QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.

Biotechnology

QurAlis

Kasper Roet

Emma Bowden

Kevin Eggan

Abi Foster

Barry F.

Sudhir Agrawal

Hagen Cramer

Vikas Sharma

Daniel Elbaum

Shirley Lasch

Chris Thomajan

Research and Development Team

Leadership Team

Finance and Administration Team

Clinical Operations Team

Regulatory Affairs and Quality Assurance Team

Teams at QurAlis

Research and Development Team

Leadership Team

Finance and Administration Team

Clinical Operations Team

Regulatory Affairs and Quality Assurance Team